How long should we give immunotherapy for?
The length of immunotherapy course for metastatic lung cancer was arbitrarily set at 2 years in clinical trials, but definitive studies investigating the optimum duration against the risk-benefit profile are lacking
How can we continue to improve outcomes for our patients with lung cancer?
Advances made in the treatment of advanced lung cancer are now being introduced at earlier stages of disease
Assessing pathological response after neoadjuvant treatment for NSCLC
Much progress has been made in the standardisation of pathological response but optimising viable tumour cutoffs for predicting long-term outcome after different treatment modalities and by histological type remain key areas for investigation